Magenta Therapeutics Inc
F:3MT
Magenta Therapeutics Inc
Total Equity
Magenta Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magenta Therapeutics Inc
F:3MT
|
Total Equity
$106m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Magenta Therapeutics Inc
Glance View
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. The company is headquartered in Cambridge, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The firm's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. The company is developing product candidates to be used individually or, in some cases, in combination with each other.
